|
| 产品描述 |
| BMS-708163 (avagacestat) is an oral GSI designed for selective inhibition of Aβ synthesis currently in development for the treatment of mild to moderate and predementia AD. In addition to the desired effect on Aβ synthesis, GSIs affect Notch processing, which is thought to mediate some toxic adverse effects reported with this drug class. Avagacestat produced up to 190-fold greater selectivity for Aβ synthesis than Notch processing in preclinical studies and may therefore produce less toxic adverse events than other less selective compounds. Results from this single-ascending dose study suggest that avagacestat was tolerated at a single-dose range of 0.3 to 800 mg and suitable for further clinical development. |
| 化学结构 |
 |
| 化学名称 |
| (R)-2-(4-chloro-N-(2-fluoro-4-(1,2,4-oxadiazol-3-yl)benzyl)phenylsulfonamido)-5,5,5-trifluoropentanamide |
| SMILES Code |
| O=C(N)[C@H](N(CC1=CC=C(C2=NOC=N2)C=C1F)S(=O)(C3=CC=C(Cl)C=C3)=O)CCC(F)(F)F |
| 基本信息 |
产品编号:XM012
产品名称:Avagacestat (BMS-708163)
CAS#:1146699-66-2
分子式:C20H17ClF4N4O4S
精确分子量:520.05952
分子量:520.88
|
| 物化性质 |
外观: Solid powder.
纯度: >98%
运输信息: 非危险化学品，适于常温或冰袋运输。
储存条件: 低温，干燥，避光。
溶解性: 溶于DMSO, 不溶于水
储存期限: 3 年 -20℃ 固体储存 2 年 -80℃ 溶液储存 |
该产品只供科研使用，不能给病人提供。
|
|
|
